{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:59:11Z","timestamp":1793879951363,"version":"4.7.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP E83C22004670001"],"award-info":[{"award-number":["CUP E83C22004670001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["20222FYK9R"],"award-info":[{"award-number":["20222FYK9R"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neurobiolaging.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T10:59:26Z","timestamp":1751713166000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Serum HDL-cholesterol is associated with the clinical-biological profile of early-stage Parkinson\u2019s disease patients independently of APOE"],"prefix":"10.1016","volume":"155","author":[{"given":"Davide","family":"Mascioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bissacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bovenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Simonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Buttarazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Bagetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Sancesario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Maftei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-6278","authenticated-orcid":false,"given":"Tommaso","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00328","article-title":"Dysregulated lipid metabolism and its role in \u03b1-synucleinopathy in Parkinson\u2019s disease","author":"Alecu","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib2","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1093\/brain\/awae203","article-title":"Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in Lewy body disease","volume":"147","author":"Barba","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib3","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1212\/WNL.0000000000207371","article-title":"CSF synaptic biomarkers in AT(N)-based subgroups of lewy body disease","volume":"101","author":"Barba","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/mds.28941","article-title":"Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers","volume":"37","author":"Barba","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-023-00613-8","article-title":"Cerebrospinal fluid lipoproteins inhibit \u03b1-synuclein aggregation by interacting with oligomeric species in seed amplification assays","volume":"18","author":"Bellomo","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib6","article-title":"High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: evidence from two large population cohort studies","volume":"18","author":"Beyene","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2008.06.013","article-title":"The importance of non-HDL cholesterol reporting in lipid management","author":"Blaha","year":"2008","journal-title":"J. Clin. Lipido"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib8","doi-asserted-by":"crossref","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC. Definition of a molecular pathway mediating \u03b1-synuclein neurotoxicity. J Neurosci. 2015 Apr 1;35(13):5221-32. doi: 10.1523\/JNEUROSCI.4650-14.2015. Erratum in: J Neurosci. 2024 May 22;44(21):e0790242024. doi: 10.1523\/JNEUROSCI.0790-24.2024. PMID: 25834048; PMCID: PMC4380997.","DOI":"10.1523\/JNEUROSCI.4650-14.2015"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s12035-020-02232-6","article-title":"Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets","volume":"58","author":"Dai","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-3-030-41769-7_16","article-title":"High-density lipoproteins and apolipoprotein A1","author":"van der Vorst","year":"2020","journal-title":"Subcell Biochem."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s12031-017-0942-9","article-title":"Role of apolipoproteins and \u03b1-synuclein in Parkinson\u2019s Disease","author":"Emamzadeh","year":"2017","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105273","article-title":"Retardation of A\u03b242 fibril formation by apolipoprotein A-I and recombinant HDL particles","volume":"299","author":"Frankel","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tem.2010.10.001","article-title":"High density lipoprotein: it\u2019s not just about lipid transport anymore","volume":"22","author":"Gordon","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/psyg.13122","article-title":"Association of lipid levels with motor and cognitive function and decline in Parkinson\u2019s disease","volume":"24","author":"Gu","year":"2024","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and Parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib16","article-title":"Lower blood lipid level is associated with the occurrence of Parkinson\u2019s disease: a meta-analysis and systematic review","volume":"2022","author":"Hong","year":"2022","journal-title":"Int. J. Clin. Pr."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-25180-8","article-title":"Association between serum lipid levels over time and risk of Parkinson\u2019s disease","volume":"12","author":"Hurh","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2020.04.004","article-title":"Ischemic injury precipitates neuronal vulnerability in Parkinson\u2019s disease: insights from PINK1 mouse model study and clinical retrospective data","volume":"74","author":"Imbriani","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019S. Dement."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/ene.15592","article-title":"Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: a cross-sectional study","volume":"30","author":"Jeong","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00597","article-title":"Effects of higher serum lipid levels on the risk of parkinson\u2019s disease: a systematic review and meta-analysis","author":"Jiang","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168935","article-title":"Role of lipids in the pathogenesis of Parkinson\u2019s disease","author":"Kamano","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031795","article-title":"Apolipoprotein E gene in \u03b1-synucleinopathies: a narrative review","author":"Liampas","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2018.01.010","article-title":"Parkinson\u2019s disease from the gut","volume":"1693","author":"Liddle","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib28","article-title":"Serum lipids and the pathogenesis of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"75","author":"Lu","year":"2021","journal-title":"Int. J. Clin. Pr."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib29","article-title":"The extent of human apolipoprotein a-i lipidation strongly affects the \u03b2-amyloid efflux across the blood-brain barrier in vitro","volume":"13","author":"Magro","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib30","doi-asserted-by":"crossref","unstructured":"Mahley, R.W., Innerarity, T.L., Rall, S.C., Weisgraber, K.H., 1984. Plasma lipoproteins: Apolipoprotein structure and function. J Lipid Res. https:\/\/doi.org\/10.1016\/s0022-2275(20)34443-6.","DOI":"10.1016\/S0022-2275(20)34443-6"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.06.015","article-title":"APOE \u03b54: The most prevalent yet understudied risk factor for Alzheimer\u2019s disease","author":"Michaelson","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105765","article-title":"Elevated ApoE, ApoJ and lipoprotein-bound \u03b1-synuclein levels in cerebrospinal fluid from Parkinson\u2019s disease patients \u2013 validation in the BioFIND cohort","volume":"116","author":"Paslawski","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166793","article-title":"Apolipoprotein E \u03b54 triggers neurotoxicity via cholesterol accumulation, acetylcholine dyshomeostasis, and PKC\u03b5 mislocalization in cholinergic neuronal cells","volume":"1869","author":"Piccarducci","year":"2023","journal-title":"Biochim. Et. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-023-00671-y","article-title":"Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia","author":"Poliakova","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mds.28805","article-title":"Apolipoprotein E genotype contributes to motor progression in Parkinson\u2019s disease","volume":"37","author":"Pu","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.23872","article-title":"Plasma apolipoprotein A1 as a biomarker for Parkinson disease","volume":"74","author":"Qiang","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1515374","article-title":"The role of apolipoprotein E4 on cognitive impairment in Parkinson\u2019s disease and Parkinsonisms","volume":"19","author":"Rosal","year":"2025","journal-title":"Front Neurosci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3233\/JAD-200344","article-title":"Amyloid-\u03b242\/neurogranin ratio as a potential index for cognitive impairment in Parkinson\u2019s disease","volume":"76","author":"Sancesario","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.parkreldis.2018.10.018","article-title":"CSF \u03b1-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients","volume":"61","author":"Schirinzi","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib44","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/mds.26290","article-title":"Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson\u2019s disease patients","volume":"30","author":"Swanson","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib46","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib47","article-title":"HDL and cholesterol handling in the brain","author":"Vitali","year":"2014","journal-title":"Downloaded"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0404.2009.01318.x","article-title":"Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson\u2019s disease","author":"Wang","year":"2010","journal-title":"Acta Neurol. Scand. 122 350359"},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010131","article-title":"Lipids as emerging biomarkers in neurodegenerative diseases","volume":"25","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mds.29363","article-title":"Brain and systemic inflammation in De Novo Parkinson\u2019s disease","volume":"38","author":"Yacoubian","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.00053","article-title":"Contra-directional expression of plasma superoxide dismutase with lipoprotein cholesterol and high-sensitivity C-reactive protein as important markers of Parkinson\u2019s Disease severity","volume":"12","author":"Yang","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tem.2023.05.002","article-title":"Apolipoprotein E in lipid metabolism and neurodegenerative disease","volume":"34","author":"Yang","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adc9317","article-title":"Brain lipidomics: from functional landscape to clinical significance","volume":"8","author":"Yoon","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neurobiolaging.2025.07.004_bib54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2023.07.011","article-title":"Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson\u2019s disease","volume":"131","author":"Zenuni","year":"2023","journal-title":"Neurobiol. Aging"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458025001186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458025001186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:17:39Z","timestamp":1777105059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458025001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0197458025001186"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2025.07.004","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum HDL-cholesterol is associated with the clinical-biological profile of early-stage Parkinson\u2019s disease patients independently of APOE","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}